KRRO-111
/ Korro Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 22, 2026
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
(GlobeNewswire)
- "Korro Bio, Inc...announced preclinical results for its pipeline program KRRO-111 for the potential treatment of alpha-1 antitrypsin deficiency (AATD) delivered subcutaneously...KRRO-111 exhibited potent RNA editing activity (EC50 ~1 nM) achieving up to 98% editing in mouse and human hepatocytes."
Preclinical • Alpha-1 Antitrypsin Deficiency
1 to 1
Of
1
Go to page
1